Dan Janiak joined AveXis in 2018 as Senior Director of Corporate Strategy & Business Development. AveXis is a clinical-stage gene therapy company focused on rare and orphan genetic diseases.
Previously, Dan was an Associate with DFJ Mercury, where he focused on developing and originating life science-based investment themes and startup opportunities.
Prior to DFJ Mercury, Dan was an Associate in the Physical and Biological Technologies practice at In-Q-Tel, the strategic venture investment arm of the U.S. Intelligence Community. While at In-Q-Tel, Dan was responsible for the management and oversight of technology development programs in numerous In-Q-Tel portfolio companies. In addition, he was responsible for leading technical due diligence on all potential investment candidates in the advanced materials space.
Education, Personal, and Fellowship
Dan received his BS and PhD from the University of Maryland Dan where he was a Future Faculty Fellow and held the Robert E. Fischell Fellowship in Biomedical Engineering. While at Maryland, Dan conducted research in the design, synthesis, and characterization of artificial antibodies with applications in medical diagnostics and biopharmaceutical purification.
Dan served his fellowship at Mercury Fund under the mentorship of Managing Director Dan Watkins. He is a member of Class 17.